[PMID]: | 29254478 |
[Au] Autor: | Zhang H; Yang Q; Liao K; Ni Y; Yu Y; Hu B; Sun Z; Huang W; Wang Y; Wu A; Feng X; Luo Y; Chu Y; Chen S; Cao B; Su J; Duan Q; Zhang S; Shao H; Kong H; Gui B; Hu Z; Badal R; Xu Y |
[Ad] Endereço: | Division of Microbiology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, No. 1 Shuaifuyuan, Wangfujing Street, Beijing, 100730, China. |
[Ti] Título: | Update of incidence and antimicrobial susceptibility trends of Escherichia coli and Klebsiella pneumoniae isolates from Chinese intra-abdominal infection patients. |
[So] Source: | BMC Infect Dis;17(1):776, 2017 12 18. |
[Is] ISSN: | 1471-2334 |
[Cp] País de publicação: | England |
[La] Idioma: | eng |
[Ab] Resumo: | BACKGROUND: To evaluate in vitro susceptibilities of aerobic and facultative Gram-negative bacterial (GNB) isolates from intra-abdominal infections (IAIs) to 12 selected antimicrobials in Chinese hospitals from 2012 to 2014. METHODS: Hospital acquired (HA) and community acquired (CA) IAIs were collected from 21 centers in 16 Chinese cities. Extended spectrum beta-lactamase (ESBL) status and antimicrobial susceptibilities were determined at a central laboratory using CLSI broth microdilution and interpretive standards. RESULTS: From all isolated strains the Enterobacteriaceae (81.1%) Escherichia coli accounted for 45.4% and Klebsiella pneumoniae for 20.1%, followed by Enterobacter cloacae (5.2%), Proteus mirabilis (2.1%), Citrobacter freundii (1.8%), Enterobacter aerogenes (1.8%), Klebsiella oxytoca (1.4%), Morganella morganii (1.2%), Serratia marcescens (0.7%), Citrobacter koseri (0.3%), Proteus vulgaris (0.3%) and others (1.0%). Non- Enterobacteriaceae (18.9%) included Pseudomonas aeruginosa (9.8%), Acinetobacter baumannii (6.7%), Stenotrophomonas maltophilia (0.9%), Aeromonas hydrophila (0.4%) and others (1.1%). ESBL-screen positive Escherichia coli isolates (ESBL+) showed a decreasing trend from 67.5% in 2012 to 58.9% in 2014 of all Escherichia coli isolates and the percentage of ESBL+ Klebsiella pneumoniae isolates also decreased from 2012 through 2014 (40.4% to 26.6%), which was due to reduced percentages of ESBL+ isolates in HA IAIs for both bacteria. The overall susceptibilities of all 5160 IAI isolates were 87.53% to amikacin (AMK), 78.12% to piperacillin-tazobactam (TZP) 81.41% to imipenem (IMP) and 73.12% to ertapenem (ETP). The susceptibility of ESBL-screen positive Escherichia coli strains was 96.77%-98.8% to IPM, 91.26%-93.16% to ETP, 89.48%-92.75% to AMK and 84.86%-89.34% to TZP, while ESBL-screen positive Klebsiella pneumoniae strains were 70.56%-80.15% susceptible to ETP, 80.0%-87.5% to IPM, 83.82%-87.06% to AMK and 63.53%-68.38% to TZP within the three year study. Susceptibilities to all cephalosporins and fluoroquinolones were less than 50% beside 66.5% and 56.07% to cefoxitin (FOX) for ESBL+ Escherichia coli and Klebsiella pneumoniae strains respectively. CONCLUSIONS: The total ESBL+ rates decreased in Escherichia coli and Klebsiella pneumoniae IAI isolates due to fewer prevalence in HA infections. IPM, ETP and AMK were the most effective antimicrobials against ESBL+ Escherichia coli and Klebsiella pneumoniae IAI isolates in 2012-2014 and a change of fluoroquinolone regimens for Chinese IAIs is recommended. |
[Mh] Termos MeSH primário: |
Abdome/microbiologia Antibacterianos/farmacologia Infecções por Escherichia coli/microbiologia Escherichia coli/efeitos dos fármacos Infecções por Klebsiella/microbiologia Klebsiella pneumoniae/efeitos dos fármacos
|
[Mh] Termos MeSH secundário: |
Cefalosporinas/farmacologia China/epidemiologia Infecções Comunitárias Adquiridas/epidemiologia Infecções Comunitárias Adquiridas/microbiologia Infecção Hospitalar/microbiologia Escherichia coli/classificação Escherichia coli/genética Escherichia coli/isolamento & purificação Infecções por Escherichia coli/epidemiologia Seres Humanos Imipenem/farmacologia Incidência Infecções Intra-Abdominais/microbiologia Infecções por Klebsiella/epidemiologia Klebsiella pneumoniae/classificação Klebsiella pneumoniae/genética Klebsiella pneumoniae/isolamento & purificação Testes de Sensibilidade Microbiana beta-Lactamas/farmacologia
|
[Pt] Tipo de publicação: | JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T |
[Nm] Nome de substância:
| 0 (Anti-Bacterial Agents); 0 (Cephalosporins); 0 (beta-Lactams); 71OTZ9ZE0A (Imipenem); G32F6EID2H (ertapenem) |
[Em] Mês de entrada: | 1801 |
[Cu] Atualização por classe: | 180214 |
[Lr] Data última revisão:
| 180214 |
[Sb] Subgrupo de revista: | IM |
[Da] Data de entrada para processamento: | 171220 |
[St] Status: | MEDLINE |
[do] DOI: | 10.1186/s12879-017-2873-z |
|
|